Eisensehr 2004.

Methods	Randomised controlled crossover trial of slow‐release levodopa versus slow‐release valproic acid versus placebo Dropouts/withdrawals: Total N of 20, no premature discontinuations
Participants	Included/analysed: 20/20 Demographics: 8 male, age 58.9 years Diagnosis: primary RLS according to IRLSSG, PLM/h > 10, symptoms daily for at least 6 months Setting: 1 centre in Germany Baseline: PLMSI (using PSG) 42.3 ± 40.7
Interventions	Intervention 1: fixed single dose of 200 mg/50 mg slow‐release‐levodopa/benserazide (after 2 days of 100 mg/25 mg) for 3 weeks Intervention 2: fixed single dose of slow‐release‐valproic acid (600 mg after 2 days of 300 mg) for 3 weeks Control: fixed single dose of placebo capsules for 3 weeks No washout between treatment periods
Outcomes	Change of symptoms: Rating of severity of symptoms in the past 24 hours Objective quality of sleep: TST, PLMSI (using PSG) Safety: Number of dropouts due to adverse events, number of patients experiencing adverse events
funding source	The study was supported by Sanofi pharmaceutical company.
Notes
Risk of bias
Bias	Authors' judgement	Support for judgement
Adequate sequence generation?	Unclear risk	Insufficient information.
Allocation concealment?	Low risk	Capsules were distributed when requested by blinded executor mentioning patient number and treatment session.
Blinding? All outcomes	Low risk	Similar looking and tasting capsules, physicians did not know about sequences until end of study when analysis was completed.
Incomplete outcome data addressed? All outcomes	Low risk	No incomplete outcome data.
Free of selective reporting?	Low risk	All results reported as prespecified with additional sleep data.
Free of other bias?	Low risk	Low indication of bias.